PE20181925A1 - Composiciones antineoplasicas - Google Patents

Composiciones antineoplasicas

Info

Publication number
PE20181925A1
PE20181925A1 PE2018003138A PE2018003138A PE20181925A1 PE 20181925 A1 PE20181925 A1 PE 20181925A1 PE 2018003138 A PE2018003138 A PE 2018003138A PE 2018003138 A PE2018003138 A PE 2018003138A PE 20181925 A1 PE20181925 A1 PE 20181925A1
Authority
PE
Peru
Prior art keywords
hpmcas
rna
solid dispersion
weight
antineoplastic compositions
Prior art date
Application number
PE2018003138A
Other languages
English (en)
Inventor
Johny Bertels
Jurgen Mensch
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56148120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181925(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of PE20181925A1 publication Critical patent/PE20181925A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a formulaciones farmaceuticas que comprende un vehiculo de 250 mg de acetato de abiraterona y una dispersion solida que comprende 60 mg ARN-509 y un polimero seleccionado entre HPMCAS, y un copolimero de poli(met)acrilato y mezclas de los mismos, y la relacion peso en peso de ARN-509:HPMCAS en la dispersion solida se encuentra en el rango entre 1:1 y 1:5; tambien se refiere a un proceso de preparacion. Dicha formulacion es un comprimido y es util para el tratamiento de cancer de prostata y se usa en combinacion con un glucocorticoide como la prednisona.
PE2018003138A 2016-06-03 2017-05-16 Composiciones antineoplasicas PE20181925A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172968 2016-06-03

Publications (1)

Publication Number Publication Date
PE20181925A1 true PE20181925A1 (es) 2018-12-11

Family

ID=56148120

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003138A PE20181925A1 (es) 2016-06-03 2017-05-16 Composiciones antineoplasicas

Country Status (24)

Country Link
US (1) US20190216829A1 (es)
EP (1) EP3463377A1 (es)
JP (1) JP2019517497A (es)
KR (1) KR20190015314A (es)
CN (1) CN109219437A (es)
AR (1) AR108489A1 (es)
AU (1) AU2017275396A1 (es)
BR (1) BR112018074965A2 (es)
CA (1) CA3024872A1 (es)
CL (1) CL2018003403A1 (es)
CO (1) CO2018012857A2 (es)
CR (1) CR20180600A (es)
EA (1) EA201892828A1 (es)
IL (1) IL263157A (es)
MA (1) MA45090A (es)
MX (1) MX2018014846A (es)
NI (1) NI201800127A (es)
PE (1) PE20181925A1 (es)
PH (1) PH12018502334A1 (es)
SG (1) SG11201809680QA (es)
TN (1) TN2018000366A1 (es)
TW (1) TW201808287A (es)
UA (1) UA124154C2 (es)
WO (1) WO2017209939A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791222A1 (ru) 2014-12-05 2017-09-29 Арагон Фармасьютикалз, Инк. Противораковые композиции
US10285948B2 (en) 2014-12-05 2019-05-14 Janssen Pharmaceutica Nv Anticancer compositions
CZ2016573A3 (cs) 2016-09-16 2018-03-28 Zentiva, K.S. Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
WO2019206472A1 (en) * 2018-04-26 2019-10-31 Synthon B.V. Tablet compositions comprising abiraterone acetate
WO2021009605A1 (en) * 2019-07-15 2021-01-21 Shilpa Medicare Limited Dispersible tablets of abiraterone acetate
JP2022091129A (ja) * 2020-12-08 2022-06-20 東和薬品株式会社 組成物ならびにその製造方法および用途
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
RS60617B1 (sr) 2012-06-07 2020-09-30 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
EP2969227B1 (en) * 2013-03-15 2019-05-08 Iceutica Inc. Abiraterone acetate formulation
MX386859B (es) * 2014-02-05 2025-03-19 Lek Pharmaceuticals Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
TWI831347B (zh) * 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑

Also Published As

Publication number Publication date
EP3463377A1 (en) 2019-04-10
JP2019517497A (ja) 2019-06-24
MA45090A (fr) 2021-04-28
MX2018014846A (es) 2019-03-14
WO2017209939A1 (en) 2017-12-07
TW201808287A (zh) 2018-03-16
CL2018003403A1 (es) 2019-02-01
UA124154C2 (uk) 2021-07-28
NI201800127A (es) 2019-03-29
AU2017275396A1 (en) 2018-11-22
CO2018012857A2 (es) 2018-12-14
IL263157A (en) 2018-12-31
CR20180600A (es) 2019-07-11
BR112018074965A2 (pt) 2019-03-12
KR20190015314A (ko) 2019-02-13
CN109219437A (zh) 2019-01-15
SG11201809680QA (en) 2018-11-29
CA3024872A1 (en) 2017-12-07
EA201892828A1 (ru) 2019-05-31
US20190216829A1 (en) 2019-07-18
PH12018502334A1 (en) 2019-07-29
TN2018000366A1 (en) 2020-06-15
AR108489A1 (es) 2018-08-29

Similar Documents

Publication Publication Date Title
MX2024004531A (es) Compuestos de piridazinona y usos de los mismos.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
PH12017501774A1 (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
BR112019024747A2 (pt) formulações de dose fixa
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX2017007201A (es) Composiciones anticancerigenas.
BR112018015419A2 (pt) degradantes seletivos de receptor de estrogênio e os usos dos mesmos
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR102926A1 (es) Composiciones anticancerosas
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
MX2017007206A (es) Composiciones anticancerigenas.
AR108489A1 (es) Composiciones antineoplásicas
BR112016013026A2 (pt) compostos para receptor-3 de fator de crescimento de fibroblasto (fgfr3) e métodos de tratamento
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
MX2017009482A (es) Formulación farmacéutica.
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
MX2019000717A (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.
CL2018000138A1 (es) Composicion farmaceutica solida que comprende al compuesto 1 y al compuesto 2 en dispersiones solidas amorfas, y sus perfiles de disolucion.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
MX2017013396A (es) Clonidina y/o derivados de clonidina para uso en la prevencion y/o tratamiento de efectos secundarios adversos de quimioterapia.
BR112018070580A2 (pt) métodos e composições para terapia com células t car